CRISPR Therapeutics to Present Late-Breaking Data at the American Heart Association (AHA) Scientific Sessions 2026
Key Highlights
- ➤CRISPR Therapeutics (CRSP) will present Phase 1b CTX310 data November 9, 2026.
- ➤Late-breaking oral presentation covers severe hypertriglyceridemia patients treated with in vivo gene editing.
- ➤CTX310 targets ANGPTL3 for severe hypertriglyceridemia and other dyslipidemias.
- ➤CRISPR Therapeutics’ cardiovascular pipeline includes CTX340 and CTX321 programs.
ZUG, Switzerland and BOSTON, Oct. 08, 2026 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP) today announced that clinical data from the Phase 1b trial of CTX310(®), its investigational CRISPR/Cas9 in vivo gene editing therapy targeting angiopoietin-related protein 3 (ANGPTL3), in patients with severe hypertriglyceridemia will be presented in a late-breaking oral presentation at the American Heart Association (AHA) Scientific Sessions 2026, taking place November 6 – 9, 2026.
Abstract Title: CRISPR-Cas9 Gene Editing Therapy Targeting ANGPTL3 for Severe Hypertriglyceridemia: Results From Phase 1b Trial Session Type: Late-Breaking Science (Oral Presentation) Session Title: LBS.05 New Frontiers in Cardiometabolic Risk Reduction Session Date and Time: Monday, November 9, 2026, 8:00 a.m. CST
Get started
Create a free account to read the full story.